Figure 6.
Figure 6. BM environment dependence signature of TACIhi patients and plasmablastic signature of TACIlo patients. (A) TACIhi MMCs had a BM environment dependence signature with overexpression of intercellular communication and transduction genes. (B) TACIlo MMCs have a plasmablastic signature with an overexpression of genes involved in the cell cycle. ITGA2B indicates integrin, alpha 2b; PDGF, platelet-derived growth factor beta polypeptide; IL22RA, interleukin 22 receptor alpha 1; AMN, amnionless homolog; PI3K, phosphoinositide-3-kinase; C-MET, met proto-oncogene (hepatocyte growth factor receptor); PSMA3, proteasome subunit, alpha type 3; PSMD8, proteasome subunit, non-ATPase, 8; ASK, activator of S phase kinase; CDC2, cell division cycle 2; CDC23, cell division cycle 23; BUB3, budding uninhibited by benzimidazoles 3; MCM2, minichromosome maintenance deficient 2; MCM3P, minichromosome maintenance deficient 3 associated protein; and MPHOSPH9, M phase phosphoprotein 9.

BM environment dependence signature of TACIhi patients and plasmablastic signature of TACIlo patients. (A) TACIhi MMCs had a BM environment dependence signature with overexpression of intercellular communication and transduction genes. (B) TACIlo MMCs have a plasmablastic signature with an overexpression of genes involved in the cell cycle. ITGA2B indicates integrin, alpha 2b; PDGF, platelet-derived growth factor beta polypeptide; IL22RA, interleukin 22 receptor alpha 1; AMN, amnionless homolog; PI3K, phosphoinositide-3-kinase; C-MET, met proto-oncogene (hepatocyte growth factor receptor); PSMA3, proteasome subunit, alpha type 3; PSMD8, proteasome subunit, non-ATPase, 8; ASK, activator of S phase kinase; CDC2, cell division cycle 2; CDC23, cell division cycle 23; BUB3, budding uninhibited by benzimidazoles 3; MCM2, minichromosome maintenance deficient 2; MCM3P, minichromosome maintenance deficient 3 associated protein; and MPHOSPH9, M phase phosphoprotein 9.

Close Modal

or Create an Account

Close Modal
Close Modal